Related Experiment Videos
Endothelium and the brain in CNS lupus
P L Meroni1, A Tincani, N Sepp
1Allergy and Clinical Immunology Unit, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy. pierluigi.meroni@unimit.it
Lupus
|January 13, 2004
Summary
Central nervous system (CNS) involvement in systemic lupus erythematosus (SLE) is common. Research suggests brain endothelial cells are targeted, potentially due to beta 2 glycoprotein I expression, leading to neurological symptoms.
Area of Science:
- Neurology
- Immunology
- Pathology
Background:
- Central nervous system (CNS) involvement is a frequent complication of systemic lupus erythematosus (SLE), presenting diverse clinical symptoms.
- Pathogenic mechanisms contributing to varied neurological manifestations in SLE are under investigation.
- Antiphospholipid antibodies and associated thrombophilia are implicated in noninflammatory vasculopathy, causing ischemic events and microcirculatory alterations in the brain.
Purpose of the Study:
- To explore the pathogenic mechanisms underlying CNS involvement in SLE.
- To investigate the role of brain endothelial cells as targets in SLE-related neurological damage.
- To identify specific molecular interactions contributing to CNS autoimmunity in SLE patients.
Main Methods:
- Review of existing literature on CNS involvement in SLE.
- Analysis of data on endothelial cell function and phenotype in lupus.
- Examination of the expression of beta 2 glycoprotein I on endothelial cells.
- Investigation of antiendothelial cell antibodies and their binding specificities in SLE patients with CNS involvement.
Main Results:
- Brain endothelium is a common target in both inflammatory and noninflammatory vasculopathies associated with SLE.
- Peculiar functional and phenotypical characteristics of brain endothelial cells may contribute to their susceptibility in lupus.
- Elevated expression of beta 2 glycoprotein I on endothelial cells may lead to selective damage by anti-beta 2 glycoprotein I antibodies.
- Antiendothelial cell antibodies can cross-react with brain endothelium, and in some cases, specifically bind to it in SLE patients with CNS involvement.
Conclusions:
- Brain endothelial cells are critically involved in the pathogenesis of CNS manifestations in SLE.
- Specific interactions involving beta 2 glycoprotein I and antiendothelial cell antibodies may drive selective brain endothelial cell damage in SLE.
- Understanding these mechanisms could lead to targeted therapies for neurological complications in systemic lupus erythematosus.